|
Adult Burkitt Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Akata and Mutu cell lines are derived from Burkitt's lymphoma (BL) and retain the in vivo phenotype of Epstein-Barr virus (EBV) expression that is characterized by expression of EBV-determined nuclear antigen 1 (EBNA1), EBV-encoded RNAs (EBERs) and transcripts from the BAM:HI A region (BARF0).
|
11118209 |
2000 |
|
Adult Burkitt Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
|
20570860 |
2010 |
|
Adult Burkitt Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The level of Bim is a critical regulator of B cell survival and reduced expression is a major determinant of lymphoproliferative disease in mice and humans; moreover, Bim is uniquely important in the pathogenesis of BL.
|
17653091 |
2008 |
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The present study demonstrated that flavopiridol did not induce caspase-3/7 activation, BIM, and BAX pro-apoptotic proteins but it leads to the expression changes of various proteins that inhibit proliferation and eternity in glioblastoma cell lines which have different genetic alterations.
|
27461656 |
2017 |
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11.
|
22895567 |
2012 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.
|
24425048 |
2014 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
|
24561519 |
2014 |
|
Adult Lymphoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Accordingly, by combining in vitro and in vivo studies of human BL-xenografts grown in immunodeficient RAG2(-/-)γc(-/-) mice and of murine B220(+)IgM(+) B-cell lymphomas generated in Eμ-MYC and Eμ-MYC-BIM(+/-) transgenes, we demonstrate that lymphoma chemoresistance is dictated by BIM gene dosage and is reversible on BIM reactivation by genetic manipulation or after treatment with histone-deacetylase inhibitors.
|
20570860 |
2010 |
|
Adult Lymphoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have indicated that some patients with positive mutations were refractory to EGFR TKIs if they harbored a B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (Bim) deletion polymorphism.
|
24737648 |
2014 |
|
Adult Lymphoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The authors' previous study demonstrated that the B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (BCL2L11) (Bim) deletion polymorphism was associated with poor clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
|
28346673 |
2017 |
|
Adult Lymphoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We have previously reported that deletion of BIM or BMF stabilizes donor stem cell numbers during transplantation and improves cellular fitness and transplantation outcomes, albeit posing a risk for lymphoma and autoimmunity in recipient mice.
|
30156339 |
2018 |
|
Adult Lymphoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Despite its limitations, this retrospective study suggests that BAM combination is a valid conditioning regimen in lymphoma patients, with an acceptable rate of toxicity.
|
31111177 |
2019 |
|
Adult Non-Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium.
|
23047821 |
2012 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our observations indicate that Bim is a proapoptotic effector of Abeta and of dysregulated cell cycle proteins in AD and identify both Bim and cell cycle elements as potential therapeutic targets.
|
17251431 |
2007 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here we show that BIM-BH3, the primary proapoptotic domain of BIM, a key protein in varied apoptotic cascades of which elevated levels have been found in brain cells of patients afflicted with Alzheimer's disease, interacts with the 42-residue amyloid isoform Aβ42.
|
31141342 |
2019 |
|
Ameloblastoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
On the basis of our results, the transcription of the apoptosis-related gene BCL2L11 is possibly regulated by promoter DNA methylation in ameloblastoma.
|
28248452 |
2017 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report that beta-amyloid (Abeta), a death-promoting peptide implicated in the pathophysiology of AD, induces the proapoptotic protein Bcl-2 interacting mediator of cell death (Bim) in cultured hippocampal and cortical neurons.
|
17251431 |
2007 |
|
Anemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Surprisingly, concurrent loss of BIM or PUMA had no significant impact on the development of anemia following acute BCL-XL deletion in vivo.
|
28682312 |
2017 |
|
Atrial Premature Complexes
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This recruitment of BIM is enhanced in cells lacking APC.
|
22399804 |
2012 |
|
Autoimmune Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
We have previously reported that deletion of BIM or BMF stabilizes donor stem cell numbers during transplantation and improves cellular fitness and transplantation outcomes, albeit posing a risk for lymphoma and autoimmunity in recipient mice.
|
30156339 |
2018 |
|
Autoimmune Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Identifying factors that facilitate apoptosis of mcDC by increasing BIM activity in a cell type-specific manner may help prevent autoimmunity.
|
29754432 |
2018 |
|
Autoimmune Lymphoproliferative Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In fact, T cells from an ALPS type IV patient in which BIM expression is suppressed were more resistant to restimulation-induced death.
|
18715501 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Alterations in the apoptosis-related regulators B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), Bcl-2-interacting mediator of cell death (Bim), apoptotic protease-activating facter-1 (Apaf-1), caspase-9 and caspase-3 were determined using reverse transcription-polymerase chain reaction (PCR) and quantitative PCR methods.
|
28693160 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the miRNA‑lncRNA‑mRNA network, miR‑20a and B‑cell lymphoma 2‑like 11 (BCL2L11) were among the top 10 nodes.
|
30720100 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, FOXO3 down-regulated expression of the anti-apoptosis gene B-cell lymphoma 2 (Bcl-2) and up-regulated the expression of the pro-apoptosis gene Bcl-2-like 11 (Bim) after entering the nucleus, eventually causing cellular apoptosis.
|
30778283 |
2019 |